




RealRate

PHARMACEUTICAL 2018

Filana Therapeutics INC
Rank 166 of 332



The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Filana Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 100% points. The greatest weakness of Filana Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 271%, being 19% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	10,663
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,132
Liabilities, Non-Current	0
Other Assets	12
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	38
Property and Equipment	156
Research and Development	7,615
Selling, General and Administrative Expense	4,334

Output Variable	Value in 1000 USD
Assets	10,831
Liabilities	1,132
Expenses	11,949
Revenues	38
Stockholders Equity	9,699
Net Income	-11,911
Comprehensive Net Income	-11,911
BaseVar	11,975
ECR before LimitedLiability	154%
Economic Capital Ratio	271%